News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boston Strategics Corporation Initiates A Phase 1 Clinical Trial Of The Anti-Cancer Agent "FF-10501" For FUJIFILM In Patients With Advanced Hematologic Malignancies


9/2/2014 1:31:26 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOSTON--(BUSINESS WIRE)--Boston Strategics Corporation (BSC), a primary global strategic drug development provider for FUJIFILM Pharmaceuticals U.S.A., Inc. (FPHU), has begun a Phase 1 clinical trial of FUJIFILM’s anti-cancer agent FF-10501 in the United States in patients with advanced hematologic malignancies, such as relapsed or refractory high-risk myelodysplastic syndromes (MDS). The trial is carried out at the University of Texas MD Anderson Cancer Center (MD Anderson) with Guillermo Garcia-Manero, M.D., Professor, as the Principal Investigator. Prof. Garcia-Manero is a world-renowned expert in advanced hematologic malignancies, especially MDS.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES